Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ACHIEVE-2 (vs dapagliflozin)

ACHIEVE-2 (vs dapagliflozin)

Orforglipron · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
t2d
Official title
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2024-01 → 2025-09
Participants
962
Duration
40 weeks
Registry
NCT06192108

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 3 mg vs dapagliflozin 10 mg (active)t2d40240——−3.5 %
estimand not specified
−1.3——19.67.93.3—verified
orforglipron 12 mg vs dapagliflozin 10 mg (active)t2d40241——−6.3 %
estimand not specified
−1.7——17.88.35.8—verified
orforglipron 36 mg vs dapagliflozin 10 mg (active)t2d40241——−7.3 %
estimand not specified
−1.7——22.412.04.1—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (15)
  • orforglipron 3 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
  • orforglipron 3 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
  • orforglipron 3 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG000", "numEvents": 60, "numAffected": 47, "numAtRisk": 240
  • orforglipron 3 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 240
  • orforglipron 3 mg · sae · CT.gov event groups
    "id": "EG000", "title": "Orforglipron 3 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated at week 4 to a dose of 3 mg, which was then maintained up
  • orforglipron 12 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
  • orforglipron 12 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
  • orforglipron 12 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG001", "numEvents": 57, "numAffected": 43, "numAtRisk": 241
  • orforglipron 12 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG001", "numEvents": 34, "numAffected": 20, "numAtRisk": 241
  • orforglipron 12 mg · sae · CT.gov event groups
    "id": "EG001", "title": "Orforglipron 12 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) unti
  • orforglipron 36 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
  • orforglipron 36 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
  • orforglipron 36 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG002", "numEvents": 70, "numAffected": 54, "numAtRisk": 241
  • orforglipron 36 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG002", "numEvents": 50, "numAffected": 29, "numAtRisk": 241
  • orforglipron 36 mg · sae · CT.gov event groups
    "id": "EG002", "title": "Orforglipron 36 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg a

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ACHIEVE-2 (vs dapagliflozin). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.